[Corrigendum] Establishment of hypoxia induction in an in vivo animal replacement model for experimental evaluation of pancreatic cancer
Affiliations: Molecular Oncosurgery, Department of General and Transplantation Surgery, University of Heidelberg and German Cancer Research Center (DKFZ), D-69120 Heidelberg, Germany
- Published online on: September 11, 2023 https://doi.org/10.3892/or.2023.8626
- Article Number: 189
Copyright : © Bauer et al. This is an open access article distributed under the terms of Creative Commons Attribution License [CC BY 4.0].
This article is mentioned in:
Oncol Rep 32: [Related article:] 153–158, 2014; DOI: 10.3892/or.2014.3196
Subsequently to the publication of the above paper, an interested reader drew to the authors' attention that, on p. 156, the data panels shown to represent the ‘CoCl2’ and ‘TRIP’ data panels in Fig. 3 for the DAPI experiments were apparently the same, even though different experiments were being depicted here.
The human markers cytokeratin 19 and Ki67 ensure induction of hypoxia in human xenograft cells. Representative images of double immunofluorescence stainings of frozen tumor xenograft sections (×400, magnification) with the proliferation marker Ki67 (red) and the cytoskeletal marker cytokeratin 19 (Cyt19, green); both detect specifically human cells. Nuclei were stained with DAPI (blue). The bar indicates 50 µm.
The authors were able to re-examine their original data files, and realized that this figure had been assembled incorrectly: there was an inadvertent mix-up of a pair of the DAPI control images. The revised version of Fig. 3, containing the correct DAPI data for the ‘TRIP’ experiment, is shown opposite. Note that the revisions made to this figure do not affect the overall conclusions reported in the paper. The authors are grateful to the Editor of Oncology Reports for allowing them the opportunity to publish this Corrigendum, and apologize to the readership for any inconvenience caused.